Evidence map›Paper›PMID 33242164›Full record

ArticleBreast cancer research and treatment2021

Tumor phenotype and concordance in synchronous bilateral breast cancer in young women.

Linda M Pak, Rachel Gaither, Shoshana M Rosenberg, Kathryn J Ruddy, Rulla M Tamimi, Jeffrey Peppercorn, Lidia Schapira, Virginia F Borges, Steven E Come, Ellen Warner and 4 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01468246 (Helping Ourselves, Helping Others), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01468246 active not recruitingnot on this map

Helping Ourselves, Helping Others: The Young Women's Breast Cancer Study

TypeobservationalSponsorDana-Farber Cancer InstituteRan2006 to 2035Enrolled1,302ConditionsBreast Cancer
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 2 countries.

Linda M PakDepartment of Surgery, Brigham and Women's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1938-3921
Rachel GaitherDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.
Shoshana M RosenbergDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.
Kathryn J RuddyDepartment of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Rulla M TamimiDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Jeffrey PeppercornDepartment of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA.
Lidia SchapiraDepartment of Medical Oncology, Stanford University, Palo Alto, CA, USA.
Virginia F BorgesDepartment of Medical Oncology, University of Colorado Cancer Center, Aurora, CO, USA.
Steven E ComeHarvard Medical School, Boston, MA, USA.
Ellen WarnerDepartment of Medical Oncology, Sunnybrook Hospital, Toronto, Canada.
Craig SnowDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.
Laura C CollinsDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.
Tari A KingDepartment of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Ann H PartridgeDepartment of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. Ann_Partridge@dfci.harvard.edu.
Dana-Farber Cancer Institute · USBrigham and Women's Hospital · USHarvard University · USBeth Israel Deaconess Medical Center · USCornell University · USMassachusetts General Hospital · USMayo Clinic · USStanford University · USSunnybrook Hospital · CAUniversity of Colorado Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSynchronous bilateral breast cancer is uncommon, and its pattern and incidence among younger women is unknown. Here we report the incidence, phenotypes, and long-term oncologic outcomes of bilateral breast cancer in women enrolled in the Young Women's Breast Cancer Study (YWS).

methodsThe YWS is a multi-center, prospective cohort study of women with breast cancer diagnosed at age ≤ 40 years. Those with synchronous bilateral breast cancer formed our study cohort. Tumor phenotypes were categorized as luminal A (hormone receptor (HR)+/HER2-/grade 1/2), luminal B (HR+ /HER2+ or HER2- and grade 3), HER2-enriched (HR-/HER2+), or basal-like (HR-/HER2-). Descriptive statistics were used to evaluate tumor phenotypes of bilateral cancers for concordance.

resultsAmong 1302 patients enrolled in the YWS, 21 (1.6%) patients had synchronous bilateral disease. The median age of diagnosis was 38 years (range 18-40 years). Seventeen (81.0%) underwent genetic testing with 6 found to have pathogenic germline mutations in BRCA1, BRCA2, or TP53. The majority of patients (76.2%) underwent bilateral mastectomy. On pathology, 2 patients had bilateral in-situ disease, 6 had unilateral invasive and contralateral in-situ disease, and 13 had bilateral invasive disease. Of those with bilateral invasive disease, 10 (76.9%) had bilateral luminal tumors and, when fully characterized, 6 were of the same luminal subtype. Only 1 patient had bilateral basal-like breast cancer. At median follow-up of 8.2 years, 14 patients are alive with no recurrent disease.

conclusionsBilateral breast cancer is uncommon among young women diagnosed with breast cancer at age ≤ 40. In our cohort, the majority of invasive tumors were of the luminal phenotype, though some differed by grade or HER2 status. These findings support the need for thorough pathologic workup of bilateral disease when it is found in young women with breast cancer to determine risk and tailor treatment.

Indexed as

Breast NeoplasmsAdolescentAdultErb-b2 Receptor Tyrosine KinasesFemaleHumansMastectomyPhenotypeProspective StudiesReceptors, EstrogenReceptors, ProgesteroneYoung AdultErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneBreast cancerSynchronous breast cancerTumor phenotypeYoung women

Identifiers

PMID33242164
OpenAlexW3110381708

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.